Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.

Boryung Pharm's original antihypertensive drug continues to increase its global presence, this time through the biggest license agreement so far for the product, with Zuellig Pharma, which will enable the South Korean pharma to sell fimasartan in the rapidly growing Southeast Asian markets.

U.S. distributor Cardinal Health goes full speed ahead in China. It has bought local players to tap into the regional market, doubled direct-to-patient pharmacies, and provided pharmacy management services to large hospitals among endeavors in the past three and a half years with more to come.